Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02764801 · ClinicalTrials.gov registry record · Phase 3
Contrast-enhanced Ultrasound Evaluation of Chemoembolization
A Phase 3 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Phase 3
- Development phase
- 131
- Enrollment target
NCT02764801 is a Phase 3 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 131 participants.
The verdict
NCT02764801, a Phase 3 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 131 participants
- Enrollment target
Study Summary
The primary objective of this trial is to evaluate the sensitivity and specificity of 2D and 4D contrast enhanced ultrasound for monitoring transarterial chemoembolization (TACE) response 1-2 weeks and 1 month post treatment as an alternative to contrast-enhanced magnetic resonance (MRI) or computed tomography (CT) imaging
Interventions
- DRUG Ultrasound contrast agent (Contrast-enhanced ultrasound)
- DEVICE Logiq E9 Scanner (Contrast-enhanced ultrasound)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2016-04 |
| Est. Completion | 2023-02-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02764801
The ClinicalTrials.gov registry entry for NCT02764801 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ultrasound contrast agent (Contrast-enhanced ultrasound) is the first listed.
NCT02764801 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02764801 about?
NCT02764801 is a clinical study titled "Contrast-enhanced Ultrasound Evaluation of Chemoembolization". The primary objective of this trial is to evaluate the sensitivity and specificity of 2D and 4D contrast enhanced ultrasound for monitoring transarterial chemoembolization (TACE) response 1-2 weeks and 1 month post treatment as an alternative to contrast-enhanced magnetic resonance (MRI) or computed...
What is the current status of trial NCT02764801?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 131 participants. The study started on 2016-04. Estimated completion is 2023-02-01.
What interventions are being tested in trial NCT02764801?
The interventions under investigation include: Ultrasound contrast agent (Contrast-enhanced ultrasound) (DRUG), Logiq E9 Scanner (Contrast-enhanced ultrasound) (DEVICE).
Who is sponsoring clinical trial NCT02764801?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.